Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.
ONCOLOGY Vol 38, Issue 8
The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.
Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.
Krystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia
ByMuhammad Hamza Gul, MBBS, MD,Aisha Rehman Siddiqui, MBBS, MD,Farwa Zehra, MBBS,Malaika Rehmani, MBBS,Faraz Waheed, MBBS,Natasha Masood, MBBS,Maleeha Saqib, MBBS,Mahnoor Keen, MBBS, MD,Sharan Siddharth Keshetty, MD,Maham Maqsood, MBBS,Siddharth Arjun Atwal, MD,Muhammad Hamza Sikandari, MBBS,Abdul Baseer Wardak, MBBS
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
3
FDA Approves Revumenib in R/R NPM1-Mutant AML
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
